# Icatibant Acetate (Sajazir)

Source: https://ourhealthnetwork.com/drugs/icatibant-acetate
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Icatibant Acetate?

Icatibant Acetate (brand name: Sajazir) is a bradykinin b2 receptor antagonists. It is prescribed to treat angioedemas, hereditary. Across the United States, 49 doctors prescribe Icatibant to approximately 39 Medicare patients.

## Brand names

Sajazir

## Indications

Icatibant Acetate is prescribed for the treatment of angioedemas and hereditary.

## Conditions treated

- [Angioedemas](https://ourhealthnetwork.com/conditions/angioedemas)
- [Hereditary](https://ourhealthnetwork.com/conditions/hereditary)

## Mechanism of action

Icatibant is a competitive antagonist selective for the bradykinin B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production.

## Drug classification

- Established Pharmacologic Class: bradykinin B2 receptor antagonists
- Route of administration: SUBCUTANEOUS

## Common side effects

shown in table 1, which occurred in almost all patients

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)